The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME ... causing fluid leakage and swelling in the macula — the part of the eye responsible ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema. Susvimo is the first and only FDA-approved treatment shown to ...

Diabetic macular edema (DME ... This fluid buildup leads to retinal swelling, which can cause blurred vision and, if left untreated, may result in significant vision loss or blindness.

Diabetic Macular Edema Overview Diabetic Macular Edema ... causing them to leak fluid and leading to swelling in the macula. This swelling disrupts vision and can result in blurred or distorted ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...